Wall Street Zen upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a strong sell rating to a hold rating in a research note published on Saturday.
A number of other research analysts have also recently issued reports on the company. JonesTrading lowered their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Finally, Chardan Capital lowered their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ProQR Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.33.
Check Out Our Latest Stock Analysis on ProQR Therapeutics
ProQR Therapeutics Stock Performance
Insider Activity at ProQR Therapeutics
In other ProQR Therapeutics news, CEO Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock in a transaction on Thursday, July 9th. The stock was acquired at an average price of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer owned 300,000 shares in the company, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bart Filius bought 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The stock was acquired at an average cost of $1.72 per share, with a total value of $258,000.00. Following the acquisition, the director owned 300,000 shares in the company, valued at approximately $516,000. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 600,000 shares of company stock worth $988,500 over the last ninety days. 8.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On ProQR Therapeutics
Several institutional investors have recently modified their holdings of PRQR. Osaic Holdings Inc. raised its position in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $35,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth approximately $51,000. Axiom Investment Management LLC bought a new stake in shares of ProQR Therapeutics in the first quarter worth approximately $53,000. Finally, Simplex Trading LLC raised its holdings in shares of ProQR Therapeutics by 44,169.0% during the fourth quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 44,169 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.
Featured Articles
- Five stocks we like better than ProQR Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
